(6-methoxy-pyridin-3-yl)-carbamic acid phenyl ester | 102671-59-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (6-methoxy-pyridin-3-yl)-carbamic acid phenyl ester
• 英文别名: 2-Methoxy-5-(phenoxycarbonylamino)pyridine；phenyl (6-methoxypyridin-3-yl)carbamate；phenyl 6-methoxypyridin-3-ylcarbamate；phenyl N-(6-methoxypyridin-3-yl)carbamate
• CAS: 102671-59-0
• 化学式: C₁₃H₁₂N₂O₃
• mdl: MFCD14861340
• 分子量: 244.25
• InChiKey: JJNOYKFXGGQMBN-UHFFFAOYSA-N

物化性质

• 沸点：
  357.5±42.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  60.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (6-methoxy-pyridin-3-yl)-carbamic acid phenyl ester 在 盐酸 作用下， 以 水 、 乙腈 为溶剂， 生成 1-((R)-1-{6-(2,2-diphenyl-ethylamino)-9-[(1R,2S,3R,4S)-4-(5-ethyl-tetrazol-2-yl)-2,3-dihydroxy-cyclopentyl]-9H-purin-2-yl}-pyrrolidin-3-yl)-3-(6-methoxy-pyridin-3-yl)-urea hydrochloride
  参考文献：
  名称：

  WO2007/121923

  摘要：

  公开号：
• 作为产物：
  描述：

  5-氨基-2-甲氧基吡啶 、 氯甲酸苯酯 在 吡啶 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 (6-methoxy-pyridin-3-yl)-carbamic acid phenyl ester
  参考文献：
  名称：

  Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines

  摘要：

  提供了能够调节NPY5受体活性的替代螺环[异苯并呋喃-1,4′-哌啶]-3-酮和3H-螺环异苯并呋喃-1,4′-哌啶。这些化合物可用于在体内或体外调节NPY5受体的配体结合，并且在治疗各种疾病（例如，肥胖或暴食症等进食障碍、精神障碍、糖尿病和高血压等心血管疾病）方面对人类、驯养的伴侣动物和家畜动物特别有用。提供了用于治疗这些疾病的药物组合物和方法，以及用于检测NPY5受体的这些化合物的方法。

  公开号：

  US20030036652A1

文献信息

• Biaryl Ether Urea Compounds
  申请人：FAY Lorraine Kathleen

  公开号：US20080261941A1

  公开（公告）日：2008-10-23

  The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity.

  本发明涉及式(I)的化合物或其药用可接受的盐；制备该化合物的方法；制备该化合物所用的中间体；含有该化合物的组合物；以及利用该化合物治疗与脂肪酸酰胺水解酶(FAAH)活性相关的疾病或症状。
• [EN] HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] MODULATEURS D'AMIDE D'ACIDE GRAS HYDROLASE DE TYPE DIAMINE URÉE SPIROCYCLIQUE SUBSTITUÉE PAR UN GROUPE HÉTÉROARYLE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010141817A1

  公开（公告）日：2010-12-09

  Certain heteroaryl-substituted spirocyclic diamine urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).

  描述了某些杂环取代的螺环二胺脲化合物，这些化合物可用作FAAH抑制剂。这些化合物可用于制药组合物和治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、紊乱和条件的方法，如焦虑、疼痛、炎症、睡眠紊乱、进食紊乱、能量代谢紊乱和运动紊乱（例如多发性硬化）。
• Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
  申请人：Bakthavatchalam Rajagopal

  公开号：US20050033048A1

  公开（公告）日：2005-02-10

  Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and method for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.

  本文提供了能够调节NPY5受体活性的取代的spiro[异苯并呋喃-1,4'-哌啶]-3-酮和3H-spiro异苯并呋喃-1,4'-哌啶。这些化合物可以用于体内或体外调节NPY5受体的配体结合，并且在人类、宠物和家畜动物的多种疾病治疗中特别有用（例如，饮食失调如肥胖症或贪食症、精神障碍、糖尿病和心血管疾病如高血压）。提供了制药组合物和治疗这些疾病的方法，以及使用这些化合物检测NPY5受体的方法。
• Spiro&lsqb;isobenzofuran-1,4′-piperidin&rsqb;-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines
  申请人：Pfizer Inc.

  公开号：US06566367B2

  公开（公告）日：2003-05-20

  Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.

  本发明提供了能够调节NPY5受体活性的取代的螺[异苯并呋喃-1,4'-哌啶]-3-酮和3H-螺异苯并呋喃-1,4'-哌啶类化合物。这些化合物可用于体内或体外调节配体与NPY5受体的结合，并在治疗多种疾病（例如，饮食失调，如肥胖症或贪食症，精神障碍，糖尿病和心血管疾病，如高血压）的人类、家养伴侣动物和家畜动物中特别有用。还提供了用于治疗这些疾病的制药组合物和方法，以及用于检测NPY5受体的方法。
• Organic Compounds
  申请人：Fairhurst Robin Alec

  公开号：US20080207648A1

  公开（公告）日：2008-08-28

  Compounds of formula I in free or salt form, wherein R 1 , R 2 and R 3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A 2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  公式I的化合物，无论是自由形式还是盐形式，其中R1、R2和R3的含义如规范中所示，对于治疗由腺苷A2A受体激活介导的炎症或阻塞性呼吸道疾病非常有用。还描述了含有这些化合物的制药组合物以及制备这些化合物的过程。